<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d285" origId="Bevacizumab"><sentence id="DrugDDI.d285.s0" origId="s0" text="No formal drug interaction studies with anti-neoplastic agents have been conducted."><entity id="DrugDDI.d285.s0.e0" origId="s0.p2" charOffset="40-62" type="drug" text="anti-neoplastic agents"/></sentence><sentence id="DrugDDI.d285.s1" origId="s1" text="In Study 1, patients with colorectal cancer were given irinotecan/5-FU/leucovorin (bolus-IFL) with or without AVASTIN."><entity id="DrugDDI.d285.s1.e0" origId="s1.p11" charOffset="55-65" type="drug" text="irinotecan"/><entity id="DrugDDI.d285.s1.e1" origId="s1.p17" charOffset="110-117" type="drug" text="AVASTIN"/><pair id="DrugDDI.d285.s1.p0" e1="DrugDDI.d285.s1.e0" e2="DrugDDI.d285.s1.e1" interaction="?"/></sentence><sentence id="DrugDDI.d285.s2" origId="s2" text="Irinotecan concentrations were similar in patients receiving bolus-IFL alone and in combination with AVASTIN."><entity id="DrugDDI.d285.s2.e0" origId="s2.p18" charOffset="0-10" type="drug" text="Irinotecan"/><entity id="DrugDDI.d285.s2.e1" origId="s2.p26" charOffset="101-108" type="drug" text="AVASTIN"/><pair id="DrugDDI.d285.s2.p0" e1="DrugDDI.d285.s2.e0" e2="DrugDDI.d285.s2.e1" interaction="?"/></sentence><sentence id="DrugDDI.d285.s3" origId="s3" text="The concentrations of SN38, the active metabolite of irinotecan, were on average 33% higher in patients receiving bolus-IFL in combination with AVASTIN when compared with bolus-IFL alone."><entity id="DrugDDI.d285.s3.e0" origId="s3.p29" charOffset="32-49" type="drug" text="active metabolite"/><entity id="DrugDDI.d285.s3.e1" origId="s3.p30" charOffset="53-63" type="drug" text="irinotecan"/><entity id="DrugDDI.d285.s3.e2" origId="s3.p37" charOffset="144-151" type="drug" text="AVASTIN"/><pair id="DrugDDI.d285.s3.p0" e1="DrugDDI.d285.s3.e0" e2="DrugDDI.d285.s3.e1" interaction="?"/><pair id="DrugDDI.d285.s3.p1" e1="DrugDDI.d285.s3.e0" e2="DrugDDI.d285.s3.e2" interaction="?"/><pair id="DrugDDI.d285.s3.p2" e1="DrugDDI.d285.s3.e1" e2="DrugDDI.d285.s3.e2" interaction="?"/></sentence><sentence id="DrugDDI.d285.s4" origId="s4" text="In Study 1, patients receiving bolus-IFL plus AVASTIN had a higher incidence of Grade 3-4 diarrhea and neutropenia."><entity id="DrugDDI.d285.s4.e0" origId="s4.p46" charOffset="46-53" type="drug" text="AVASTIN"/></sentence><sentence id="DrugDDI.d285.s5" origId="s5" text="Due to high inter-patient variability and limited sampling, the extent of the increase in SN38 levels in patients receiving concurrent irinotecan and AVASTIN is uncertain."><entity id="DrugDDI.d285.s5.e0" origId="s5.p60" charOffset="135-145" type="drug" text="irinotecan"/><entity id="DrugDDI.d285.s5.e1" origId="s5.p62" charOffset="150-157" type="drug" text="AVASTIN"/><pair id="DrugDDI.d285.s5.p0" e1="DrugDDI.d285.s5.e0" e2="DrugDDI.d285.s5.e1" interaction="?"/></sentence></document>